We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Molecular Detection and Palex Medical Announce Distribution Agreement for Detect-Ready™ MRSA Assay in Spain


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Molecular Detection and Palex Medical Announce Distribution Agreement for Detect-Ready™ MRSA Assay in Spain"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed for infectious disease diagnosis, and Palex Medical S.A., a distributors of medical device and diagnostic products to hospitals in Spain, have announced that they have entered into an exclusive distribution agreement for MDI’s Detect-Ready™ MRSA assay in Spain.

Palex Medical is an independent distributor of a wide range of medical products including clinical diagnostics, consumables and specialized surgical tools. The Detect-Ready™ MRSA assay offers healthcare providers a high-performance MRSA screening test. Palex recently launched the Detect-Ready™ MRSA assay into the Spanish market.

Drug-resistant, potentially deadly MRSA (methicillin-resistant Staphylococcus aureus) infections are a growing problem in healthcare facilities around the world. The Detect-Ready™ MRSA kit is a qualitative real-time PCR (rt-PCR) in vitro diagnostic test for the direct detection of MRSA nasal colonization to aid in the prevention and control of MRSA infections in hospitals and other healthcare settings.

According to Molecular Detection, the proprietary technology in the Detect-Ready™ kits provides a differential diagnosis engine that produces accurate results, minimizing the false positives and false negatives experienced with other MRSA screening kits. Samples for testing are simple to obtain using nasal swabs, and the assay’s ready-to-use pre-mixed reagents require only the addition of patient sample to run the test, which provides results in less than three hours.

“Spain is introducing proactive control programs to combat the major problem that MRSA infections pose to health facilities worldwide, and we believe that the combination of accuracy, speed, versatility and cost-effectiveness of the Detect-Ready™ MRSA assay will contribute to the success of these efforts,” said Josep Maria Espinalt, General Manager of Palex Medical S.A. “Our dedicated team of highly skilled professionals is committed to bringing our expertise and infrastructure to help ensure the clinical and commercial success of the Detect-Ready™ MRSA assay in Spain.”
Advertisement